The experiment’s design was parallel, randomized, and double-blind. A 300 mg injection of inclisiran was administered to individuals having Atherosclerotic cardiovascular disease at irregular intervals on days 1, 90, 270, and 450...
Most Recent Articles
VISUALIZED: Comparison Between Ticagrelor and Clopidogrel In CYP2C19 Loss-of-Function Carriers With Stroke or Transient Ischemic Attack—CHANCE-2
Read further: Comparison Between Ticagrelor and Clopidogrel In CYP2C19 Loss-of-Function Carriers With Stroke or Transient Ischemic Attack—CHANCE-2
Comparison Between Ticagrelor and Clopidogrel In CYP2C19 Loss-of-Function Carriers With Stroke or Transient Ischemic Attack—CHANCE-2
The investigation's objective was to compare the effectiveness of ticagrelor plus aspirin vs. clopidogrel and aspirin in decreasing the risk of future stroke who had already experienced a stroke or an elevated transient ischemic...
Diagnosis and Intervention Guidelines on Aortic Disease by the American Heart Association and American College of Cardiology
The "2022 American Heart Association Framework for the Diagnosis and Management of Aortic Disease" offers suggestions to help healthcare professionals with diagnostic testing, genetic analysis, kinship screening, pharmacological...
VISUALIZED: Hospital OPPS Final Rule Released by CMS: Summary and Key Points
Read further: Hospital OPPS Final Rule Released by CMS: Summary and Key Points
